

# Enhancing Cosmesis While Achieving High Cure Rates for Early Stage Non-Melanoma Skin Cancer in the Outpatient Dermatology Clinic Using a Novel Non-Invasive Modality

Lio Yu<sup>1</sup>, Mairead Moloney<sup>2\*</sup>, Raymond Beers<sup>3</sup> and Donna Serure<sup>4</sup>

<sup>1</sup>Director of Radiation Oncology, Laserderm Dermatology, USA

<sup>2</sup>New York Institute of Technology College of Osteopathic Medicine, Old Westbury, USA

<sup>3</sup>Astarita Associates, Smithtown, USA

<sup>4</sup>Chief of Dermatology, Laserderm Dermatology, USA

## ARTICLE INFO

Received Date: April 20, 2022

Accepted Date: May 23, 2022

Published Date: May 25, 2022

## KEYWORDS

Image-guided superficial radiation therapy

Non-melanoma skin cancer

Basal cell carcinoma

Squamous cell carcinoma

Squamous cell carcinoma in situ

**Copyright:** © 2022 Mairead Moloney et al., Clinical Dermatology: Research And Therapy. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**Citation for this article:** Lio Yu, Mairead Moloney, Raymond Beers, and Donna Serure. Enhancing Cosmesis While Achieving High Cure Rates for Early Stage Non-Melanoma Skin Cancer in the Outpatient Dermatology Clinic Using a Novel Non-Invasive Modality. Clinical Dermatology: Research And Therapy. 2022; 4(1):134

## Corresponding author:

Mairead Moloney,  
New York Institute of Technology College of Osteopathic Medicine, Old Westbury, South Setauket, NY 11720, New York, Tel: + (631) - 655-8019;  
Email: maireadmoloney@gmail.com

## ABSTRACT

**Introduction:** Non-Melanoma Skin Cancer(NMSC) is generally treated in dermatology offices using surgical techniques.

**Objectives:** We evaluate the feasibility, tolerance, effectiveness and cosmesis using an office-based non-surgical modality for NMSC.

**Methods:** 93 patients with 133 pathologically confirmed early stage invasive and in-situ NMSC lesions treated with Image-Guided Superficial Radiation Therapy (IGSRT) were retrospectively analyzed. All lesions received a median of twenty fractions of 50 or 70 kilovoltage(kV) IGSRT. Energy selection and subsequent kV changes were determined by ultrasound imaging. RTOG toxicity scoring was used. Treatment interruption was defined as greater than 2 weeks.

**Results:** Median age was 69. At an average follow-up of 16.23 months, 92 of 93 patients were alive. One patient expired from unrelated causes while no evidence of disease (NED). 132 of 133 lesions achieved local control (LC) with one lesion recurring at 12.9 months. Absolute LC was 99.2%, overall Kaplan-Meier LC (KM LC) was 98.95% at 30.8 months, and Disease Free Survival (DFS) was 100%. Acute toxicities were mild with RTOG grades 0, 1 or 2 in all lesions with no grade 3 or 4 toxicity. Cosmesis was felt to be excellent or very good (VG) by the clinicians with no fair/poor cosmesis. There were no severe toxicities or complications requiring treatment interruptions.

**Conclusions:** Office based IGSRT is feasible, safe, easily tolerable, and highly effective. Patients receiving IGSRT achieve excellent/VG cosmesis and welcome this nonsurgical option. IGSRT is an attractive non-invasive therapeutic option for NMSC and provides another valuable tool for dermatologists.

## ABBREVIATIONS

AAD: American Academy of Dermatology; ADLs: Activities of Daily Living; AJCC: American Joint Committee on Cancer; ASTRO: American Society for Radiation Oncology; BCC: Basal cell carcinoma; cGy: Centigray; cm: Centimeter; cSCC: Cutaneous Squamous Cell Carcinoma; DFS: Disease Free Survival; ED&C: Electrodesiccation and Curettage; FTA: Full Thickness Atypia; IGSRT: Image-guided

Superficial Radiation Therapy; KM: Kaplan-Meier; kV: Kilovoltage; LC: Local Control; LLE: Limited Life Expectancy; mm: Millimeter; MMS: Mohs Micrographic Surgery; NCCN: National Comprehensive Cancer Network; NED: No Evidence of Disease; NMSC: Non-Melanoma Skin Cancer; RCT: Randomized Controlled Trial; RT: Radiation Therapy; RTOG: Radiation Treatment Oncology Group; sBCC: Superficial Basal Cell Carcinoma; SCC: Squamous Cell Carcinoma; SCCIS: Squamous Cell Carcinoma in situ; SD: Standard Deviation; SRT: Superficial Radiation Therapy; TDF: Time Dose Fractionation; VG: Very good; 5-FU: 5-Fluorouracil

## INTRODUCTION

The incidence of skin cancer is on the rise for both melanoma and Non-Melanoma Skin Cancer (NMSC) with NMSC being 18 to 20 times higher than melanoma [1]. NMSC is the most prevalent cancer in the United States with the current estimate indicating 3.3 million patients with 5.43 million lesions in 2012 [2,3]. NMSC comprises of various types of non-melanoma skin malignancies, the majority of which comprise of Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC), which are keratinocyte carcinomas [4]. BCC and SCC account for 99% of NMSC, with BCC making up 80% of skin cancers [1,4,5]. In the United States, there are between 5.03 to 5.23 million BCC lesions diagnosed each year and there are between 200,000 to 400,000 cases of SCC each year [6,7]. Major risk factors for the development of NMSC include duration and intensity of sun exposure, increased age and fair skin, which is why Caucasians over 65 are at the greatest risk for developing skin cancer [5,8-10]. The greatest incidence of NMSC occurs in sun-exposed areas including the head and neck. Consequently it is imperative that we identify treatment modalities that result in high cure rates and superior cosmesis [5,7].

Despite the high occurrence of NMSC, they are considered nonfatal and curable due to their slow growth, low recurrence, and rare metastasis with limited impact on mortality and morbidity [9,10]. However, it is standard that NMSC are treated to prevent invasion and tumor growth [4,5]. Additionally, small superficial cutaneous squamous cell carcinoma, if left untreated, can locally invade and lead to metastasis and potential mortality. Treatment modalities include Mohs Micrographic Surgery (MMS), surgical excision, radiation

therapy, Electrodesiccation and Curettage (ED&C), cryotherapy, laser, photodynamic therapy, topical medications and systemic medications [2,4,9,10]. Although there are a variety of less invasive non-surgical options available for the treatment of NMSC, surgery remains the standard for NMSC treatment, specifically Mohs micrographic surgery [5]. This is due to the fact that current evidence suggests MMS offers the highest cure rates, with about a 1% 5-year recurrence for BCC and less than 6% 5-year recurrence for SCC [11,12]. A drawback of MMS for NMSC is that in anatomical locations where conservation of tissue is important, such as the ear, nose, eyelid and neck, MMS removes tissue layers posing cosmetic concerns [4,5,7,8].

Another concern is that a majority of NMSC occur in older patients, who might not be able to endure the length of time in the surgical position MMS requires to excise the skin cancer in addition to the sequela that follows after surgery [9,11]. Linos *et al.* reported that patients with a Limited Life Expectancy (LLE) may not benefit from surgical removal of NMSC when compared to patients who received non-surgical treatment or no treatment [9]. Individuals with LLE typically have difficulty with activities of daily living (ADLs) and would likely need assistance with wound care after surgery [5]. A non-surgical treatment option would minimize the complications of skin surgery, such as infection, excessive bleeding, and wound dehiscence. Furthermore, a non-surgical approach is attractive to patients who are not medically surgical candidates, such as those with cardiac risk factors, on blood thinners, or otherwise precluded from having surgery. Nonsurgical options have the potential to maintain better cosmesis and function with minimal pain.

## OBJECTIVE

We report early results of a non-surgical modality for the treatment of NMSC – Image-Guided Superficial Radiation Therapy (IGSRT). This newer image guided treatment combines the use of ultrasound for non-invasive imaging and an established treatment of superficial radiation therapy, which has been used for decades [12].

## METHODS

### Patient selection

We retrospectively analyzed the medical charts of 93 patients (60 female, 33 male) from an outpatient dermatology practice

in Smithtown, NY. The authors adhered to the principles established in the Federal Policy for the Protection of Human Subjects, referred to as the "Common Rule," as well as the pertinent sections of the Helsinki Declaration and its amendments. The data have been de-identified for use in this study.

Table 1: Treatment characteristics for IGSRT (Image-Guided Superficial Radiation Therapy).		
IG-SRT Treatment Characteristics		
Total dose received (cGy)	Mean	5128.53 (SD +/- 140.93)
	Median	5128
	Minimum	4783
	Maximum	6032.57
Number of fractions	Mean	19.94 (SD +/- 1.02)
	Median	20
	Minimum	13
	Maximum	24
Dose per fraction (cGy)	Mean	257.06 (SD +/- 14.96)
	Median	256
	Minimum	242
	Maximum	383
Energy (kV) [Number of lesions]	50 kV	110 (82.7%)
	70 kV	9 (6.8%)
	100 kV	0 (0%)
	Mixed - 50 kV & 70 kV	14 (10.5%)
Treatment duration (months)	Mean	1.56 (SD +/- 0.26)
	Median	1.58
	Minimum	0.99
	Maximum	2.83
Treatment duration (weeks)	Mean	6.82 (SD +/- 1.12)
	Median	6.86
	Minimum	4.29
	Maximum	12.29
Time Dose Fractionation	Mean	88.35 (SD +/- 3.23)
	Median	88
	Minimum	81
	Maximum	105

Patients with pathologically confirmed early stage (Stage 0, I, II) NMSC lesions, specified by 8<sup>th</sup> edition of the American Joint Committee on Cancer (AJCC) Staging Manual [13] treated with IGSRT between April 2017 and August 2018 were analyzed. All BCC and non-head and neck cutaneous SCC (cSCC) that fell outside of AJCC staging (which currently only include head and neck cSCC) were included and staging was extrapolated to those lesions for consistency. SCC In-Situ (SCCIS) lesions were only selected for treatment if they had Full Thickness Atypia (FTA) deemed appropriate for treatment by NCCN guidelines

[14]. Lesions from patients with multiple NMSC lesions treated synchronously or metachronously with IGSRT were included in the study for a total of 133 lesions. The histopathology and stage for all lesions were confirmed prior to IGSRT treatment. All patients signed informed consent prior to treatment.

Table 2: RTOG (Radiation Treatment Oncology Group) acute skin radiation toxicity [15].	
Grade	Signs / Symptoms
0	No symptoms
1	Follicular, faint or dull erythema; epilation; dry desquamation; decreased sweating
2	Tender or bright erythema, patchy moist desquamation; moderate edema
3	Confluent, moist desquamation other than skin folds, pitting edema
4	Ulceration, hemorrhage, necrosis
5	Death directly related to radiation effects

### Treatment methods

Patient's lesions were generally treated with 50, 70, or mixed (50 and 70) kilo Voltage(kV) energy IGSRT given 3 or 4 times weekly (range 2-4) (Table 1). Lesions were treated with a median of 20 fractions of 256cGy (range 242 to 283cGy) for a total cumulative dose of 5128cGy over 1.58 months. The protocol used recommended a typical dose fractionation in the range of 245-265 cGy for 20 fractions as a routine and can vary somewhat based on tumor characteristics, size of treatment cone applicator, histology and depth of the lesion ultrasound. The IGSRT machine is not designed to deliver doses based on cGy dose but instead based on time (minutes) the beam is turned on to 2 decimal points. Therefore, the treatment dose that comes closest to that recommended by the protocol doses is generally selected. Energy selection and subsequent kV changes were determined by ultrasound imaging of the lesion and clinical exam characteristics. Doses were prescribed to the skin surface. Acute toxicities were graded using Radiation Treatment Oncology Group (RTOG) toxicity scoring (Table 2) [15]. Radiation RTOG toxicity scoring was used throughout the treatment every 1 to 2 weeks generally after every 5 fractions. The highest RTOG score was recorded for this retrospective analysis. Treatment interruption was defined as an unplanned break due to side effects of greater than 2 weeks. Patients were generally followed initially 2-4 weeks

after treatment completion and scheduled for continued follow-up until there was No Evidence of Disease (NED) or if failure occurred. Thereafter or contemporaneously, patients returned to their dermatologists for follow-up and management.

Board-certified Radiation Therapists administered each fraction based on the IGSRT prescription determined by the Radiation Oncologist. A Medical Physicist ensured that all calculations and treatment parameters were in accordance with the prescription, as well as verifying the accurate completion of the treatment course. The Medical Physicist also maintained quality and safety checks on the SRT machine on a regular basis.

### Cosmesis

Cosmesis was graded by the radiation oncologist and dermatologist on a four-point standard scale based on the RTOG and European Organization for Research and Treatment of Cancer (EORTC) Late Radiation Morbidity Scoring Schema for skin and subcutaneous tissue (Table 3) [15].

Table 3: RTOG (Radiation Treatment Oncology Group) and EORTC (European Organization for Research and Treatment of Cancer) Late Radiation Morbidity Scoring Schema for skin and subcutaneous tissue [15].

Grade	Description
Excellent/Very Good	No changes to slight atrophy, pigment change, some hair loss, slight induration (fibrosis) and loss of subcutaneous fat.
Good	Patch atrophy, moderate telangiectasia, and total hair loss. Moderate fibrosis but asymptomatic. Slight field contracture with less than 10% linear reduction.
Fair	Market atrophy and gross telangiectasia. Severe induration and loss of subcutaneous tissue. Field contracture greater than 10% linear measurement.
Poor	Ulceration or necrosis

### Statistical analysis

Because follow-up time differed from patient to patient, we also used Kaplan-Meier analysis to calculate local control rates. Statistical differences were calculated using the log-rank test. P value <0.05 was considered statistically significant. Kaplan-Meier analysis and descriptive statistical analysis was performed with R Studio. Any missing data was not included in the statistical analyses.

## RESULTS

This study analyzed 93 patients with 133 lesions receiving IGSRT with a median age of 69 at first treatment (Table 4). 60

patients were female (64.5%) and 33 patients were male (35.5%). Average follow-up after IGSRT treatment was 16.23 months (SD +/- 8.88). Lesion characteristics are shown in (Table 5). 100 of the 133 lesions (75.2%) were located on the head and neck. Anatomical distribution of the NMSC lesions is shown in (Table 6). Of the total of 133 lesions, 67 were BCC, 17 were SCC, 49 were SCCIS with full thickness atypia. Forty-nine lesions were stage 0 (zero), 77 lesions were stage I, and 7 lesions were stage II. Median lesion size was 1.0cm. Seventy-four lesions had diameters greater than or equal to 1cm. Six lesions were greater than 2cm in dimension with 3 of these lesions (all SCCIS) greater than 3cm in dimension.

### Response




Figure 1: Kaplan-Meier (KM) Local control (LC) for all 133 lesions (67 BCC, 17 SCC, 49 SCCIS) treated with IGSRT (Image-Guided Superficial Radiation Therapy). Dots represent censored events.

**Local control:** Initially, all lesions achieved Local Control (LC) within 4 months. One lesion recurred at 12.9 months post treatment. Absolute Local Control (LC) rate was 99.2%. Overall Kaplan-Meier (KM) LC was 98.95% at the maximum follow-up time of 30.8 months (2.57 years) (Figure 1). There was no significant difference in KM LC between stages (Log-rank  $p=0.6729$ ) (Figure 2). KM LC for stage 0 (SCCIS) is 100% at 12, 24 and 30.8 months. KM LC for stage I is 100% at 12 months, and remained at 98.11% for 24 and 30.8 months. KM LC for stage II remained at 100% at 12, 24 and 30.8 months.

**Survival:** Disease Free Survival (DFS) at 30.8 months was 100%. At an average follow-up of 16.23 months, 92 of 93 patients were alive. One patient expired from unrelated causes while NED.




Figure 2: Kaplan-Meier (KM) Local control by stage (LC) of 133 lesions (Stage 0 = 49, Stage 1 = 77, Stage 2 = 7) treated with IGSRT (Image-Guided Superficial Radiation Therapy). Dots represent censored events.

Table 4: Patient demographics at the time of treatment.

Patient Characteristics		
Total Patients		93
Age at 1st treatment (years)	Mean	68.72 (SD +/- 10.9)
	Median	69
	Minimum	36
	Maximum	89
Gender	Female	60 (64.5%)
	Male	33 (35.5%)
Follow-up interval (months)	Mean	16.23 (SD +/- 8.88)
	Median	19.3
	Minimum	0
	Maximum	30.8

### Recurrence

The only recurrence in this cohort was a stage I nodular BCC lesion located on the ear which recurred at 12.9 months. This lesion received 20 fractions at 50kV of 251.79 cGy for a total cumulative dose of 5035.80 cGy. The Time Dose Fractionation (TDF) number for this lesion was 85. Treatment duration for this lesion was 1.64 months, which was within 1 Standard Deviation (SD) of the average treatment duration (1.56 months +/- 0.27 days). On follow-up 14 weeks after IGSRT completion, the lesion was noted as "well healed and no evidence of recurrence". Recurrence was detected 56 weeks later (12.9

months) and confirmed by biopsy with pathology showing nodular BCC. Salvage with excision and electrodesiccation was performed. Pathology after salvage, excision and ED & C confirmed scar with no residual lesion identified.

Table 5: Tumor characteristics at time of treatment.

Tumor Characteristics		
Number of Lesions		133
Histopathology	BCC	67 (50.4%)
	SCC	17 (12.8%)
	SCCIS	49 (36.8%)
Stage	T0	49 (36.8%)
	T1	77 (57.9%)
	T2	7 (5.3%)
	T3	0 (0%)
	T4	0 (0%)
Lesion Size (cm)	Mean	1.04 (SD +/- 0.63)
	Median	1.0
	Minimum	0.11
	Maximum	4.5*

\*SCCIS (Squamous Cell Carcinoma In Situ) all with full thickness atypia.

### Cosmesis

Cosmesis was felt to be almost entirely excellent and occasionally Very Good (VG) by the radiation oncologist and dermatologist with no fair or poor cosmesis. Patients were generally very satisfied with the availability and results of this non-surgical option and agreed with the excellent/very good and good cosmesis assessment of the practitioners. This also translated to many patients returning for further future treatments on new lesions.

### Toxicities

Table 7 shows the distribution by RTOG toxicity. All lesions had minimal or mild toxicity (RTOG 0, 1, 2) with no lesions having severe or significant toxicity (RTOG 3, 4). There were no severe toxicities or complications requiring treatment interruption or delay.



Table 6: Anatomic distribution of NMSC lesions.

Anatomic Distribution of Lesions	
Head and neck (H&N)	100/133 (75.2%)
H&N sublocation	
Scalp	7/133 (5.3%)
Ear	10/133 (7.5%)
Forehead	16/133 (12.0%)
Temple	4/133 (3.0%)
Lid Margin	1/133 (0.8%)
Nose	30/133 (22.6%)
Cheek	24/133 (18.0%)
Cutaneous Lip	3/133 (2.3%)
Chin	1/133 (0.8%)
Neck	4/133 (3.0%)
Chest	4/133 (3.0%)
Extremities	18/133 (13.5%)
Hand	5/133 (3.8%)
Shoulder	1/133 (0.8%)
Back	5/133 (3.8%)

Table 7: Acute toxicities RTOG (Radiation Treatment Oncology Group) grades for lesions treated with IGSRT (Image-Guided Superficial Radiation Therapy).

RTOG	Number of lesions
0	1
1	101
2	31
3	0
4	0

## DISCUSSION

There is presently very little modern data on the use of superficial radiotherapy for the treatment of NMSC. The American Academy of Dermatology (AAD) recommends superficial radiation therapy as a secondary treatment option reserved for special cases of NMSC [16,17]. This suggests that further research is necessary to establish the long-term efficacy and safety of SRT to establish that it provides comparable or acceptable cure rates in relation to MMS. The American Society for Radiation Oncology (ASTRO) analyzed the literature from May 1988 to June 2018 of studies that utilized Radiotherapy (RT) for curative intent of BCC and cSCC lesions and concluded

that there is limited modern Randomized Controlled Trials (RCT) on RT and an absence of prospective RCT comparing NMSC treatment modalities [18]. Furthermore, there is even fewer data involving use of the newer technology of IGSRT, which this retrospective study reports.

In this retrospective study, IGSRT was found to be feasible, effective, safe, convenient, and achieves excellent/VG cosmetic outcomes. These results highlight the promise that IGSRT may be considered a first line alternative non-surgical option for the treatment of NMSC. These results are also consistent with the limited current published literature which support the use of SRT for the treatment of NMSC. Roth et al. evaluated the effectiveness of SRT to treat 38 BCC and 113 SCC lesions located on the lower extremity in an elderly population with a mean age of 82.5 [19]. The follow-up for a majority of patients was > 2 years, with 17% followed < 2 years. The overall cure rate was found to be 97.4% with four lesions that recurred and successfully salvaged. Another recent study published by Roth et al., retrospectively evaluated the long-term safety and efficacy of using SRT to treat NMSC in 516 patients with 776 lesions (448 BCC and 328 SCC) [20]. Six recurrences were noted (0.77%) with a KM local control rate of 98.9% at 7.1 years and the only minor long-term toxicity was hypopigmentation. The results from both of these studies are consistent with our findings using IGSRT.

Cognetta et al. concluded that SRT was a viable non-surgical option for the treatment of NMSC with 5-year KM LC of 95.8% for BCC and 94.2% for SCC (invasive and in situ) in 1715 NMSC lesions located on the face and scalp from 1149 patients [21]. They also report a 2-year KM recurrence rate of 2% for BCC, 1.2% for invasive SCC, and 1.9% for SCCIS. The 5-year recurrence rate reported in Cognetta et al. was compared to a 5-year recurrence rate of 1.0% for BCC and a 5-year recurrence rate of 2.6% for primary SCC treated with MMS. One difference between the regimen by Cognetta et al. and ours is the fractionation regimen used. Most lesions in their series were treated with 5 fractions of 700 cGy for a total cumulative dose of 3500 cGy. In our study, we routinely used 20 fractions of approximately 255 cGy for a total cumulative dose in the range of 5100 cGy. Another difference in our study is the use of image guidance to determine the tumor depth before, during, and after treatment. Our results are similar in

comparison to Cagnetta et al. with a slightly improved 2-year KM recurrence rate for SCC and SCCIS. We report a 2-year KM recurrence rate of 2.22% for BCC, 0% for invasive SCC and 0% for SCCIS and these early results concur with those of Cagnetta et al..

Non-surgical treatment modalities for NMSC include external beam radiation, brachytherapy, 5-FU, imiquimod, and Erivedge. Our reported results with IGSRT compare well with the local control and cosmetic outcomes of these non-surgical modalities. Electron-beam radiation therapy has an estimated local control rate of 90% to 100% and a 5-year control rate of 80% for SCC and 92% for BCC, respectively; with 93% control for primary NMSC and 80% control for recurrent NMSC [22,23]. IGSRT compares favorably with the local control, post-treatment skin changes and cosmetic outcome. Brachytherapy is another radiotherapy treatment modality for NMSC where the radioactive source is applied to a surface-mold that is fitted to the tumor [23]. Brachytherapy has a local control rate ranging from 85% to 100% and is comparable to our IGSRT findings [22,24]. In 7 of 10 brachytherapy studies reviewed, cosmetic outcome was reported showing 94.8% of cases with excellent to good cosmesis [25]. Their favorable cosmetic findings as well as the low incidence of severe toxicity are consistent with our experience using IGSRT.

Topical non-surgical treatments for NMSC include 5-Fluorouracil (5-FU) and Imiquimod. One 5-FU case series reported a 90% histologic cure rate with an average treatment duration of 10.5 weeks [26]. However, high recurrence rates may be observed, with a 70% 5-year tumor free survival reported for sBCC as 5-FU has small skin penetration and should be limited to superficial BCCs and SCCs [27]. Randomized Controlled Trials (RCTs) of Imiquimod for the treatment of sBCC with various treatment regimens (ie. 2x/day, 1x/day, 5x/week, 3x/week) have shown treatment responses up to 100% [28]. However, high recurrence rates may be observed as one study reported the 5-year tumor free survival to be 80.5% after treatment of sBCC with Imiquimod [27]. One study reported 81.8% (121/148) and 84.7% (133/157) of sBCC lesions treated with Imiquimod and 5-FU, respectively, had good or excellent cosmesis [27]. Our findings with IGSRT compare favorably with these topical non-surgical methods. Longer follow-up however is necessary for our study to

compare 5-year tumor free survival. As with topical agents, IGSRT often provides a cosmetic advantage to surgical treatment as there is no cutting involved [29].

The first oral targeted therapy drug for the treatment of locally advanced, recurrent, or metastatic BCC, known as Vismodegib (Erivedge) has a reported overall response rate of 42.9% for locally advanced BCC and 30.3% for metastatic BCC [30]. These advanced tumors are typically out of the treatment scope of lesions recommended for IGSRT.

Our study further demonstrates that superficial radiotherapy combined with an image-guided modality does not detract from its effectiveness and may in fact enhance its effectiveness. There appears to be additional benefits of using image guidance as it can allow visualization of tumor dimensions even under the surface of the skin for better targeting accuracy as well as the reliable assessment of tumor depth. This is akin to the advantages of using polarized dermoscopy to help elucidate a lesion that is only visualized on the surface. The measurement of tumor depth is important as it allows selection of the proper penetrating energy to adequately encompass the entire tumor. The proper selection of energy can improve cosmetic results as normal tissue that is left unperturbed maintains a better cosmesis. On the other hand, if the energy used is not sufficient to cover the entire tumor, this can potentially result in decreased local control. The only lesion that recurred in our study was treated with an energy of 50 kV and had a relatively low TDF of 85. Our protocol currently increases the energy to 70 kV or higher and also increases the TDF number for nodular BCC lesions and is anticipated to decrease failure rates going forward. Furthermore, ultrasound use can detect potential satellite lesions or unexpected deep involvement which may change the management from non-surgical to surgical recommendations. The principles of image guidance in improving radiotherapy outcome has been documented in various previous studies on different sites of disease in the radiation treatment of neoplasms [31-33].

This study suggests IGSRT has advantages over surgery for NMSCs, especially lesions located in cosmetically sensitive areas, such as the head and neck where a majority of NMSC lesions occur, where cosmetic and functional outcome is paramount. Having a NMSC treated in a vulnerable area, such as the face, is often associated with patient anxiety and

concern about the cosmetic outcome especially with surgery [10]. In this study IGSRT appears to be able to achieve this without compromise in the control rate. Current research indicates after an individual's first NMSC, the risk for another one is 40.7% within 5 years [34]. For individuals diagnosed with a non-first NMSC the 5-year probability of another NMSC increases to 82.0%. Many patients suffer surgical fatigue from having multiple surgical procedures on an ongoing basis. In patients who may fear or decline surgery, IGSRT provides a viable and effective non-surgical option for these patients. Additionally, IGSRT is advantageous to treat NMSC in areas prone to poor wound healing, bleeding and infections (ie. below the knee, or very mobile or exposed portions of the skin). For patients who are on anticoagulation, the treatment can be given without suspension of the use of anticoagulants, minimizing the risk of stroke or thrombotic events. Patients are very pleased with the results and availability of this non-surgical option and frequently request this option for additional lesions that occur after their first experience. From the providers' experience with IGSRT, there is improved patient compliance with treating their skin cancers versus ignoring them given this additional option.

Limitations of this study include that it is a retrospective observational study on a small number of lesions with less than 5-year follow-up. No randomization was employed. Amatched cohort analysis may be beneficial to compare the results of this modality to other surgical techniques as randomization to a surgical versus non-surgical treatment may be ethically or practically difficult to accomplish. Another drawback is the use of provider reporting of recurrences, which introduces a potential underreporting bias. Results of long-term cosmetic changes and any potential late/chronic radiation toxicities generally require years if not decades of follow up which is beyond the scope/timing of this study. Further follow-up with a minimum of 2-year and preferably 5-year follow-up is warranted.

## CONCLUSIONS

Office based IGSRT is feasible, safe, and easily tolerable. On early follow-up, this 20-fraction regimen is highly effective with an overall absolute LC of 99.2%, and an overall KM LC of 98.95% at 30.8 months, with a 100% DFS. It achieves excellent or very good cosmesis and patients are very happy with the

results and availability of this nonsurgical option. IGSRT is an attractive non-invasive therapeutic option for NMSC and provides another valuable tool for dermatologists. Longer follow-up is underway.

## ACKNOWLEDGMENTS FOR GRANTS AND TECHNICAL SUPPORT

The authors would like to acknowledge the following people who were instrumental in collecting and extracting data: Nick Natalizio, Krupal Patel, and Songzhu Zhang. We extend a special thanks to Songzhu Zhang for his invaluable assistance in statistical analyses and curve generation.

## CONFLICTS OF INTEREST

We would like to disclose the following potential conflicts of interest: Dr. Lio Yu is the National Radiation Oncologist for Skin Cure Oncology and has received research, speaking and/or consulting support from Skin Cure Oncology. He has served on an advisory board for Bayer Pharmaceuticals previously. Raymond Beers, M.S works for Astarita Associates, which Skin Cure Oncology contracts with to provide physics support to Laserderm Dermatology of Smithtown. Dr. Donna Serure has no conflicts of interest to disclose. Mairead Moloney has no conflicts of interest to disclose.

## COMPLIANCE WITH ETHICS GUIDELINES

The authors adhered to the principles established in the Federal Policy for the Protection of Human Subjects, referred to as the "Common Rule," as well as the pertinent sections of the Helsinki Declaration and its amendments. The data have been de-identified for use in this study.

## REFERENCES

1. Apalla Z, Lallas A, Sotiriou E, Lazaridou E, Ioannides D. (2007). Epidemiological trends in skin cancer What Does the Future Hold. *Dermatol Pract Concept*. 7: 1-6.
2. Rong Y, Zuo L, Shang L, Bazan JG. (2015). Radiotherapy treatment for nonmelanoma skin cancer. *Expert Rev Anticancer Ther*. 15: 765-776.
3. American Cancer Society. (2020). *Cancer Facts & Figures*. American Cancer Society.
4. Fahradyan A, Howell A, Wolfswinkel E, Tsuha M, Sheth P, et al. (2017). Updates on the Management of Non-Melanoma Skin Cancer (NMSC). *Healthcare*. 5: 82.



5. Garcovich S, Colloca G, Sollena P, Andrea B, Balducci L, et al. (2017). Skin cancer epidemics in the elderly as an emerging issue in geriatric oncology. *Aging Dis.* 8: 643-661.
6. Rogers HW, Weinstock MA, Feldman SR, Coldiron BM. (2015). Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the us population, 2012. *JAMA Dermatology.* 151: 1081-1086.
7. John Kim YS, Kozlow JH, Mittal B, Moyer J, Olenecki T, et al. (2018). Guidelines of care for the management of cutaneous squamous cell carcinoma. *J Am Acad Dermatol.* 78: 560-578.
8. Nestor MS, Berman B, Goldberg D, Cognetta AB Jr, Gold M, et al. (2019). Consensus Guidelines on the Use of Superficial Radiation Therapy for Treating Nonmelanoma Skin Cancers and Keloids. *J Clin Aesthet Dermatol.* 12: 12-18.
9. Linos E, Parvataneni R, Stuart SE, Boscardin WJ, Landefeld CS, et al. (2013). Treatment of nonfatal conditions at the end of life: Nonmelanoma skin cancer. *JAMA Intern Med.* 173: 1006-1012.
10. Zagrodnik B, Kempf W, Seifert B, Müller B, Burg G, et al. (2003). Superficial Radiotherapy for Patients with Basal Cell Carcinoma: Recurrence Rates, Histologic Subtypes, and Expression of p53 and Bcl-2. *Cancer.* 98: 2708-2714.
11. Patel R, Strimling R, Doggett S, Willoughby M, Kenneth Miller K, et al. (2017). Comparison of electronic brachytherapy and Mohs micrographic surgery for the treatment of early-stage non-melanoma skin cancer: a matched pair cohort study. *J Contemp Brachytherapy.* 9: 338-344.
12. McGregor S, Minni J, Herold D. (2015). Superficial radiation therapy for the treatment of nonmelanoma skin cancers. *J Clin Aesthet Dermatol.* 8: 12-14.
13. Amin MB, Edge S, Greene FB, Brookland RK, Washington Mk, et al. (2017). *AJCC Cancer Staging Manual.* 8th ed. New York, NY: Springer.
14. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). (2020). Squamous Cell Skin Cancer. National Comprehensive Cancer Network.
15. Cox JD, Stetz JA, Pajak TF. (1995). Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European organization for research and treatment of cancer (EORTC). *Int J Radiat Oncol Biol Phys.* 31: 1341-1346.
16. American Academy of Dermatology. (2016). Position statement on superficial radiation therapy for basal cell carcinoma (BCC) and squamous cell carcinomas (SCC). <https://www.aad.org/%0AForms/Policies/Uploads/PS/P S-Superficial%2520Radiation%25%0A20Therapy.pdf>.
17. Bichakjian CK, Alam M. (2018). Reply to: "Comment on 'Guidelines of care for the management of basal cell carcinoma.'" *J Am Acad Dermatol.* 79: e101.
18. Likhacheva A, Awan M, Barker CA, et al. (2020). Definitive and Postoperative Radiation Therapy for Basal and Squamous Cell Cancers of the Skin: Executive Summary of an American Society for Radiation Oncology Clinical Practice Guideline. *Pract Radiat Oncol.* 10: 8-20.
19. Roth WJ, Shelling M, Fishman K. (2019). Superficial Radiation Therapy: A Viable Nonsurgical Option for Treating Basal and Squamous Cell Carcinoma of the Lower Extremities. *J Drugs Dermatol.* 18: 130-134.
20. Roth W, Beer RE, Iyengar V, Bender T, Raymond I. (2020). Long-Term Efficacy and Safety of Superficial Radiation Therapy in Subjects With Nonmelanoma Skin Cancer: A Retrospective Registry Study. *J Drugs Dermatol.* 19: 163-168.
21. Cognetta AB, Howard BM, Heaton HP, Stoddard ER, Hong HG, et al. (2012). Superficial x-ray in the treatment of basal and squamous cell carcinomas: A viable option in select patients. *J Am Acad Dermatol.* 67: 1235-1241.
22. Ota K, Adar T, Dover L, Khachemoune A. (2018). Review: the reemergence of brachytherapy as treatment for non-melanoma skin cancer. *J Dermatolog Treat.* 29: 170-175.
23. Alam M, Nanda S, Mittal BB, Kim NA, Yoo S. (2011). The use of brachytherapy in the treatment of nonmelanoma skin cancer: A review. *J Am Acad Dermatol.* 65: 377-388.
24. Casey S, Awotwi-Pratt J, Bahl G. (2019). Surface Mould Brachytherapy for Skin Cancers: The British Columbia Cancer Experience. *Cureus.* 11: e6412.
25. Delishaj D, Rembielak A, Manfredi B, et al. (2016). Non-melanoma skin cancer treated with high-dose-rate brachytherapy: A review of literature. *J Contemp Brachytherapy.* 8: 533-540.

26. Gross K, Kircik L, Kricorian G. (2007). 5% 5-Fluorouracil cream for the treatment of small superficial basal cell carcinoma: Efficacy, tolerability, cosmetic outcome, and patient satisfaction. *Dermatologic Surg.* 33: 433-439.
27. Jansen MHE, Koekelkoren FHJ, Nelemans PJ, et al. (2018). Comparison of long-term cosmetic outcomes for different treatments of superficial basal cell carcinoma. *J Am Acad Dermatol.* 79: 961-964.
28. Amini S, Viera MH, Valins W, Berman B. (2010). Nonsurgical innovations in the treatment of nonmelanoma skin cancer. *J Clin Aesthet Dermatol.* 3: 20-34.
29. Ermertcan AT, Hellings PW, Cingi C. (2012). Nonmelanoma Skin Cancer of the Head and Neck: Nonsurgical Treatment. *Facial Plast Surg Clin North Am.* 20: 445-454.
30. Axelson M, Liu K, Jiang X, He K, Wang J, et al. (2013). U.S. Food and Drug Administration approval: Vismodegib for recurrent, locally advanced, or metastatic basal cell carcinoma. *Clin Cancer Res.* 19: 2289-2293.
31. Western C, Hristov D, Schlosser J. (2015). Ultrasound Imaging in Radiation Therapy: From Interfractional to Intrafractional Guidance. *Cureus.* 7: 23-24.
32. Sayan M, Vergalasova I, Hard D, Wrigth H, Archambault J, et al. (2019). Daily localization of partial breast irradiation patients with three-dimensional ultrasound imaging. *Radiat Oncol J.* 37: 259-264.
33. Bohrer M, Schröder P, Welzel G, Wertz H, Lohr F, et al. (2008). Reduced rectal toxicity with ultrasound-based image guided radiotherapy using BAT (B-mode acquisition and targeting system) for prostate cancer. *Strahlentherapie Onkol.* 184: 674-678.
34. Wehner MR, Linos E, Parvataneni R, Stuart SE, Boscardin WJ, et al. (2015). Timing of subsequent new tumors in patients who present with basal cell carcinoma or cutaneous squamous cell carcinoma. *JAMA Dermatology.* 151: 382-388.
35. Quality Assurance Program Policy and Procedures - Radiation Oncology Morbidity and Mortality Review (Internal Proprietary Documents). Beth Israel Medical Center (NY, NY), Good Samaritan Hospital (West Islip, NY), Montefiore Medical Center (Bronx, NY), Laserderm Dermatology (Smithtown, NY)